Michael G. Fradley, MD: How Does Atrial Fibrillation Affect Outcomes and Health-Care Utilization Among Patients With CLL?
ASCO 2026
Michael G. Fradley, MD, of the University of Pennsylvania School of Medicine, discusses findings from a study which evaluated impact of atrial fibrillation on cardiovascular outcomes (stroke, bleeding, heart failure) and health-care utilization in patients with chronic lymphocytic leukemia (CLL) overall, by age, and by treatment (Abstract 7042).
Mohammed Al-Jumayli, MD, of H. Lee Moffitt Cancer Center and Research Institute, discusses the effects of the use of a multimodal, digitally supported prehabilitation program among adults aged 65 years and older undergoing surgery for hepatobiliary cancer; the model was associated with favorable short-term functional performance signals and high levels of engagement (Abstract 12039).
The ASCO Post Staff
Shailender Bhatia, MD, of the University of Washington and Fred Hutchinson Cancer Center, presents data from the phase III ADAM trial, a multicenter, randomized, double-blinded, placebo-controlled study of the anti–PD-L1 antibody avelumab in patients with Merkel cell carcinoma and lymph node metastases (Abstract LBA9504).
The ASCO Post Staff
Robert C. Stein, PhD, MBBChir, FRCP, of the National Institute for Health Research University College London Hospitals Biomedical Research Centre, discusses the first results from the phase III randomized OPTIMA trial, which is comparing chemotherapy decisions made with the Prosigna (PAM50) gene expression test with standard treatment with estrogen receptor (ER)-positive, HER2-negative early breast cancer (Abstract 500).
The ASCO Post Staff
Veronica Diermayr, PhD, of EDDC and A*STAR, discusses the use of artificial intelligence (AI) driven strategy called H&E 2.0 in gastric and esophageal cancer. Researchers tested the feasibility of training deep-learning models on hematoxylin and eosin images of gastroesophageal carcinomas and their ability to predict EBC-129 antigen expression directly from these images. EBC-129 is an experimental antibody-drug conjugate that targets N256-glycosylated CEACAM5/6, which is highly expressed on solid tumors, including gastroesophageal cancers (Abstract 4018).
The ASCO Post Staff
Sara A. Hurvitz, MD, FACP, of Fred Hutchinson Cancer Center, provides an update focusing on progression-free survival after next line of treatment and subsequent therapies among patients enrolled in the ASCENT-03 trial. The study compared sacituzumab govitecan vs chemotherapy in patients with previously untreated metastatic triple-negative breast cancer (Abstract 1001).
